Tokyo, Japan

Masatoshi Ushioda

USPTO Granted Patents = 13 


 

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 12(Granted Patents)


Location History:

  • Misato, JP (2013 - 2014)
  • Saitama, JP (2016 - 2018)
  • Tokyo, JP (2013 - 2022)

Company Filing History:


Years Active: 2013-2024

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: Masatoshi Ushioda: Innovator in Pharmaceutical Chemistry

Introduction

Masatoshi Ushioda is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of receptor antagonists. With a total of 13 patents to his name, Ushioda's work has had a considerable impact on medical research and drug development.

Latest Patents

Among his latest innovations is a P2X4 receptor antagonist, which involves a diazepine derivative represented by a specific general formula. This invention focuses on the pharmacological properties of the compound, which may include various configurations of atoms and functional groups. The detailed structure of the diazepine derivative highlights its potential as a pharmacologically acceptable salt, showcasing Ushioda's expertise in medicinal chemistry.

Career Highlights

Ushioda has worked with notable organizations such as Nippon Chemiphar Co., Ltd. and Kyushu University. His experience in these institutions has allowed him to collaborate with other experts in the field and contribute to groundbreaking research in drug development.

Collaborations

Some of his notable coworkers include Shogo Sakuma and Toshiyasu Imai. Their collaborative efforts have further advanced the research and development of innovative pharmaceutical solutions.

Conclusion

Masatoshi Ushioda's contributions to pharmaceutical chemistry through his patents and collaborations underscore his role as a leading inventor in the field. His work continues to influence the development of new therapeutic agents, making a lasting impact on healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…